Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 13/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745737 | 0.87 | ESR2 (0.41) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL12327209 | 0.85 | LIPG (0.44) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL422959 | 0.82 | ESR2 (0.42) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL30376230 | 0.81 | LPL (0.47) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL748654 | 0.81 | TRPV4 (0.43) | ESR2LPLLIPG | |
| SCHEMBL30015551 | 0.81 | TRPV4 (0.43) | ESR2LPLLIPG | |
| SCHEMBL751210 | 0.81 | LPL (0.47) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL16014723 | 0.81 | ESR2 (0.41) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL13089217 | 0.79 | ESR2 (0.42) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL1668230 | 0.79 | ESR2 (0.42) | ESR2LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11446298-B2 | Pyrimidine derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3625227-B1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-14 | — | — | EP | disclosed |
| EP-3377483-B9 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3377483-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2018-09-26 | — | — | EP | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9370520-B2 | Macrocyclic LRRK2 kinase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2016-06-21 | — | — | US | disclosed |
| EP-2760453-B1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | IPSEN PHARMA SAS (FR) | 2016-05-25 | — | — | EP | disclosed |
| US-20150290198-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2015-10-15 | — | — | US | disclosed |
| US-9096609-B2 | Macrocyclic LRRK2 kinase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2015-08-04 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2760453-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-20140206683-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2014-07-24 | — | — | US | disclosed |
| WO-2013046029-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ESR2 40/4885LPL 3982/4885LIPG 3998/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | ESR2 143/4885LPL 3761/4885LIPG 3391/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ESR2 73/4885LPL 4416/4885LIPG 4358/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ESR2 143/4885LPL 3761/4885LIPG 3391/4885 |
| US-20150290198-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PINK1, PARK7 | ESR2 3597/4885LPL 2024/4885LIPG 3081/4885 |
| US-11446298-B2 | Pyrimidine derivatives | PTGER1, PTGER4, PTGER2 | ESR2 51/4885LPL 4613/4885LIPG 4502/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ESR2 143/4885LPL 3761/4885LIPG 3391/4885 |
| US-20140206683-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PINK1, PARK7 | ESR2 3597/4885LPL 2024/4885LIPG 3081/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | ESR2 26/4885LPL 4391/4885LIPG 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.